tradingkey.logo

Novo Nordisk A/S

NVO
View Detailed Chart

62.070USD

-0.560-0.89%
Close 04/25, 16:00ETQuotes delayed by 15 min
208.93BMarket Cap
14.26P/E TTM

Novo Nordisk A/S

62.070

-0.560-0.89%
Intraday
1m
30m
1h
D
W
M
D

Today

-0.89%

5 Days

+6.87%

1 Month

-13.47%

6 Months

-45.25%

Year to Date

-27.84%

1 Year

-51.07%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 15 analysts
BUY
Current Rating
101.947
Target Price
64.22%
Rising Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

160
Total
6
Median
8
Average
Company name
Ratings
Analysts
Novo Nordisk A/S
NVO
15
Biogen Inc
BIIB
37
Vertex Pharmaceuticals Inc
VRTX
34
Alnylam Pharmaceuticals Inc
ALNY
33
Amgen Inc
AMGN
33
Gilead Sciences Inc
GILD
30
1
2
3
...
32

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

1m
15m
30m
1h
D
W
M
1m
15m
30m
D
Neutral
Sell(5)
Neutral(3)
Buy(4)
Indicators
Sell(1)
Neutral(3)
Buy(2)
Indicators
Value
Direction
MACD(12,26,9)
0.716
Neutral
RSI(14)
41.073
Neutral
STOCH(KDJ)(9,3,3)
46.359
Buy
ATR(14)
3.499
Low Volatility
CCI(14)
4.334
Neutral
Williams %R
42.256
Buy
TRIX(12,20)
-0.976
Sell
StochRSI(14)
100.000
Overbought
Moving Average
Sell(4)
Neutral(0)
Buy(2)
Indicators
Value
Direction
MA5
60.050
Buy
MA10
61.962
Buy
MA20
64.238
Sell
MA50
75.121
Sell
MA100
83.716
Sell
MA200
103.874
Sell

Company

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Company codeNVO
CompanyNovo Nordisk A/S
CEOMr. Lars Fruergaard Joergensen
Websitehttps://www.novonordisk.com/